OPKO Health Q1 revenue down 28% YoY to $237.6M; net loss narrows to $0.02/share

OPKO HEALTH, INC.

2023-Q1 EPS reported -$0.02 revenue$237,577,000

Pharmaceuticals revenue up to $40.4M (vs $36.6M) driven by Rayaldee and IP transfers including $50M Merck upfront.
Diagnostics revenue plunged to $132.4M from $286.6M due to lower COVID testing and GeneDx sale; operating loss of $40M.
ModeX entered license deal with Merck for EBV vaccine MDX-2201; potential milestones up to $872.5M plus royalties.
Net loss improved to $18.3M ($0.02/share) from $55.4M ($0.08/share) in Q1 2022; cash $110.8M not including $50M April payment.
Rayaldee sales grew to $6.6M from $5.1M; NGENLA approved in 41 countries, sales underway in 17.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OPKO HEALTH, INC. reported the three months ended March 31, 2023 results: revenue $237.6 million, net income $18.3 million, EPS $0.02 per share.

Period: the three months ended March 31, 2023
Revenue: $237.6 million
Net income: $18.3 million
EPS: $0.02 per share
Result: reported results

Exact text from the filing

Consolidated total revenues for the first quarter of 2023 were $237.6 million compared with $329.2 million for the comparable period of 2022.

View on SEC.gov

Browse all earnings releases →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-012324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.